1. Search Result
Search Result
Results for "

glucose-6-phosphate dehydrogenase

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

4

Natural
Products

1

Recombinant Proteins

4

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W107464
    G6PDi-1
    5+ Cited Publications

    PDI Metabolic Disease Inflammation/Immunology
    G6PDi-1 is a reversible and non-competitive glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC50 of 0.07 μM for human G6PD. G6PDi-1 depletes NADPH most strongly in lymphocytes. G6PDi-1 markedly decreases inflammatory cytokine production in T cells .
    G6PDi-1
  • HY-W010342
    6-Aminonicotinamide
    Maximum Cited Publications
    17 Publications Verification

    NADPH Oxidase Cancer
    6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP +-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (Ki=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin (HY-17394), in killing cancer cells .
    6-Aminonicotinamide
  • HY-W012530

    Endogenous Metabolite PDI Infection Metabolic Disease
    Phenylpyruvic acid is a precursor of the antifungal compound phenyllactic acid. Phenylpyruvic acid can improve the antifungal activity of eight lactic acid bacterial strains through the addition into a dedined growth medium. Phenylpyruvic acid demonstrates improved inhibitory activity against fungal bread contaminants Aspergillus niger and Penicillium roqueforti. Phenylpyruvic acid affects enzyme activity of the pentose phosphate pathway involved in the oxidative phase in rat brain homogenates. Phenylpyruvic acid can reduce glucose-6-phosphate dehydrogenase activity .
    Phenylpyruvic acid
  • HY-125863

    G6PD

    Endogenous Metabolite Metabolic Disease Cancer
    Glucose-6-phosphate dehydrogenase, Microorganism (G6PD) is the rate-limiting enzyme of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase, Microorganism is a primary source of NADPH in antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 systems, and others. Glucose-6-phosphate dehydrogenase, Microorganism is applicable in research related to diabetes, endothelial dysfunction, cancer, and cardiomyopathy .
    Glucose-6-phosphate dehydrogenase, Microorganism
  • HY-123962
    G6PD activator AG1
    5+ Cited Publications

    NADPH Oxidase Metabolic Disease
    G6PD activator AG1 is a potent and selective glucose-6-phosphate dehydrogenase (G6PD) agonist with an EC50 of 3 μM. G6PD is an oxidoreductase that catalyzes the oxidation of glucose-6-phosphate to 6-phosphogluconolactone and the simultaneous reduction of NAD phosphate (NADP) to reduced NADP (NADPH). G6PD activator AG1 can reduce hemolysis of human erythrocytes .
    G6PD activator AG1
  • HY-W017960

    Et-HE; 1,4-DHP

    SOD Endocrinology
    Diludine (BNP-7787) is an orally effective feed additive. Diludine reduces the activity of G6PD and increases the level of superoxide dismutase (SOD). Diludine reduces the mutagenic effect of environmental pollutants, protects parental reproductive systems and improves offspring quality. Diludine is mainly applied during the transition period of dairy cows to increase milk yield and milk fat content, and improve health status during parturition. Diludine can be used in animal feeding research .
    Diludine
  • HY-125863C

    G6PD, Bacillus sp.

    Endogenous Metabolite Others
    Glucose-6-phosphate dehydrogenase, Bacillus sp. catalyzes the conversion of glucose-6-phosphate into 6-phosphogluconolactone, and produces reduced nicotinamide adenine dinucleotide phosphate (NADPH) and ribose-5-phosphate in this process. Glucose-6-phosphate dehydrogenase, Bacillus sp. can be used in research about diabetic complications .
    Glucose-6-phosphate dehydrogenase, Bacillus sp.
  • HY-W587796

    6-PGδL; 6-Phosphonoglucono-D-lactone

    Endogenous Metabolite Cardiovascular Disease Metabolic Disease Cancer
    6-Phosphoglucono-δ-lactone (6-PGδL), a reversal substrate of glucose-6-phosphate dehydrogenase (G6PD), is an intermediate compound in the oxidative branch of the pentose phosphate pathway (PPP). 6-Phosphoglucono-δ-lactone produced from D-glucose-6-phosphate by glucose-6-phosphate dehydrogenase (G6PDH) and is converted to 6-phosphoglutonate by lactonase. 6-Phosphoglucono-δ-lactone can be used for heart failure, type 2 diabetes and cancers research .
    6-Phosphoglucono-δ-lactone
  • HY-W016203

    Sodium phenylpyruvate

    Endogenous Metabolite PDI Infection Metabolic Disease
    Phenylpyruvic acid sodium is a endogenous metabolite that participates in the synthesis of 3-phenyllactic acid (PLA) by lactate dehydrogenase. Phenylpyruvic acid is a precursor of the antifungal compound phenyllactic acid. Phenylpyruvic acid can improve the antifungal activity of eight lactic acid bacterial strains through the addition into a dedined growth medium. Phenylpyruvic acid demonstrates improved inhibitory activity against fungal bread contaminants Aspergillus niger and Penicillium roqueforti. Phenylpyruvic acid affects enzyme activity of the pentose phosphate pathway involved in the oxidative phase in rat brain homogenates. Phenylpyruvic acid can reduce glucose-6-phosphate dehydrogenase activity .
    Phenylpyruvic acid sodium
  • HY-W012530R

    Reference Standards Endogenous Metabolite PDI Infection Metabolic Disease
    Phenylpyruvic acid (Standard) is the analytical standard of Phenylpyruvic acid. This product is intended for research and analytical applications. Phenylpyruvic acid is a precursor of the antifungal compound phenyllactic acid. Phenylpyruvic acid can improve the antifungal activity of eight lactic acid bacterial strains through the addition into a dedined growth medium. Phenylpyruvic acid demonstrates improved inhibitory activity against fungal bread contaminants Aspergillus niger and Penicillium roqueforti. Phenylpyruvic acid affects enzyme activity of the pentose phosphate pathway involved in the oxidative phase in rat brain homogenates. Phenylpyruvic acid can reduce glucose-6-phosphate dehydrogenase activity .
    Phenylpyruvic acid (Standard)
  • HY-125863A

    G6PD (Leuconostoc sp., recombinant)

    Endogenous Metabolite Metabolic Disease
    Glucose-6-phosphate dehydrogenase (Leuconostoc sp., recombinant) is an NADP-dependent enzyme in the pentose phosphate pathway, which is one of the ways glucose is metabolized. Glucose-6-phosphate dehydrogenase (Leuconostoc sp., recombinant) can be used to quantify ATP, glucose, and creatine kinase .
    Glucose-6-phosphate dehydrogenase (Leuconostoc sp., recombinant)
  • HY-N2093
    Vicine
    2 Publications Verification

    Drug Metabolite Cardiovascular Disease Metabolic Disease
    Vicine, an alkaloid glycoside found mainly in fava beans, is toxic in individuals who have a hereditary loss of the enzyme glucose-6-phosphate dehydrogenase and may cause haemolytic anaemia.Vicine is an inactive compound that is hydrolysed by the intestinal microflora to a highly reactive free radical generating compound, the aglycone divicine when Vicine enters the body through food .
    Vicine
  • HY-W010342R

    NADPH Oxidase Reference Standards Cancer
    6-Aminonicotinamide, a potent antimetabolite of nicotinamide, is competitive NADP+-dependent enzyme glucose-6-phosphate dehydrogenase (G6PD) inhibitor (Ki=0.46 μM). 6-Aminonicotinamide resultis ATP depletion and synergizes with DNA-crosslinking chemotherapy agents, such as Cisplatin (HY-17394), in killing cancer cells .
    6-Aminonicotinamide (Standard)
  • HY-E71039

    Biochemical Assay Reagents Others
    Chemically modified Glucose-6-phosphate Dehydrogenase, Leuconostoc mesenteroides is a cytosolic enzyme. Chemically modified Glucose-6-phosphate Dehydrogenase, Leuconostoc mesenteroides is in the pentose phosphate pathway, a metabolic pathway that supplies reducing energy to cells (such as erythrocytes) by maintaining the level of the co-enzyme nicotinamide adenine dinucleotide phosphate (NADPH) .
    Chemically modified Glucose-6-phosphate Dehydrogenase, Leuconostoc mesenteroides
  • HY-125863D

    Endogenous Metabolite Metabolic Disease
    Glucose-6-phosphate dehydrogenase, Torula yeast (EC 1.1.1.49), is a cytoplasmic enzyme located in the pentose phosphate pathway, a metabolic pathway that provides reducing energy to cells (e.g., erythrocytes) by maintaining the level of the coenzyme nicotinamide adenine dinucleotide phosphate (NADPH).
    Glucose-6-phosphate dehydrogenase, Torula yeast
  • HY-136783

    Parasite Infection
    G6PD-IN-2 is a Plasmodium falciparum glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC50 value of 0.2 μM. G6PD-IN-2 exerts weak inhibitory activity on Plasmodium falciparum glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase (PfGluPho) with an IC50 value of 22.0 μM. G6PD-IN-2 inhibits growth of Plasmodium falciparum 3D7 strain and exhibits low cytotoxicity in hepatocytes. G6PD-IN-2 can be used for the research of malaria .
    G6PD-IN-2
  • HY-W248922

    PDI Infection
    2,6-Dibromo-4-(hydroxymethyl) phenol (Compound 5) acts as a selective inhibitor of Saccharomyces cerevisiae glucose-6-phosphate dehydrogenase, with an IC50 value of 50.2 μM, and shows no activity against Leuconostoc mesenteroides glucose-6-phosphate dehydrogenase .
    2,6-Dibromo-4-(hydroxymethyl)phenol

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: